Enoxaparin versus dalteparin or tinzaparin in patients with cancer and venous thromboembolism: The RIETECAT study.
LMWH
cancer
cohort
dalteparin
enoxaparin
recurrences
tinzaparin
venous thromboembolism
Journal
Research and practice in thrombosis and haemostasis
ISSN: 2475-0379
Titre abrégé: Res Pract Thromb Haemost
Pays: United States
ID NLM: 101703775
Informations de publication
Date de publication:
May 2022
May 2022
Historique:
received:
24
05
2021
revised:
06
04
2022
accepted:
20
04
2022
entrez:
6
6
2022
pubmed:
7
6
2022
medline:
7
6
2022
Statut:
epublish
Résumé
Venous thromboembolism (VTE) is a frequent complication in patients with cancer and a leading cause of morbidity and death. The objective of the RIETECAT study was to compare the long-term effectiveness and safety of enoxaparin versus dalteparin or tinzaparin for the secondary prevention of VTE in adults with active cancer. We used the data from the multicenter, multinational RIETE registry to compare the rates of VTE recurrences, major bleeding, or death over 6 months in patients with active cancer and acute VTE using full doses of enoxaparin versus dalteparin or tinzaparin, and a multivariable Cox proportional hazard model was used to analyze the primary end point. From January 2009 to June 2018, 4451 patients with active cancer received full doses of the study drugs: enoxaparin, 3526 patients; and dalteparin or tinzaparin, 925 (754 + 171) patients. There was limited difference in VTE recurrences (2.0% vs 2.5%) and mortality rate (19% vs 17%) between the enoxaparin and dalteparin or tinzaparin subgroups. However, there was a slight numerical increase in major bleeding (3.1% vs 1.9%). Propensity score matching confirmed that there were no differences in the risk for VTE recurrences (adjusted hazard ratio [aHR], 0.81; 95% confidence interval [CI], 0.48-1.38), major bleeding (aHR, 1.40; 95% CI, 0.80-2.46), or death (aHR, 1.07; 95% CI, 0.88-1.30) between subgroups. In RIETECAT, in patients with cancer and VTE receiving full-dose enoxaparin or dalteparin or tinzaparin, no statistically significant differences were observed regarding effectiveness and safety outcomes over a 6-month period.
Sections du résumé
Background
UNASSIGNED
Venous thromboembolism (VTE) is a frequent complication in patients with cancer and a leading cause of morbidity and death.
Objectives
UNASSIGNED
The objective of the RIETECAT study was to compare the long-term effectiveness and safety of enoxaparin versus dalteparin or tinzaparin for the secondary prevention of VTE in adults with active cancer.
Methods
UNASSIGNED
We used the data from the multicenter, multinational RIETE registry to compare the rates of VTE recurrences, major bleeding, or death over 6 months in patients with active cancer and acute VTE using full doses of enoxaparin versus dalteparin or tinzaparin, and a multivariable Cox proportional hazard model was used to analyze the primary end point.
Results
UNASSIGNED
From January 2009 to June 2018, 4451 patients with active cancer received full doses of the study drugs: enoxaparin, 3526 patients; and dalteparin or tinzaparin, 925 (754 + 171) patients. There was limited difference in VTE recurrences (2.0% vs 2.5%) and mortality rate (19% vs 17%) between the enoxaparin and dalteparin or tinzaparin subgroups. However, there was a slight numerical increase in major bleeding (3.1% vs 1.9%). Propensity score matching confirmed that there were no differences in the risk for VTE recurrences (adjusted hazard ratio [aHR], 0.81; 95% confidence interval [CI], 0.48-1.38), major bleeding (aHR, 1.40; 95% CI, 0.80-2.46), or death (aHR, 1.07; 95% CI, 0.88-1.30) between subgroups.
Conclusions
UNASSIGNED
In RIETECAT, in patients with cancer and VTE receiving full-dose enoxaparin or dalteparin or tinzaparin, no statistically significant differences were observed regarding effectiveness and safety outcomes over a 6-month period.
Identifiants
pubmed: 35664535
doi: 10.1002/rth2.12736
pii: S2475-0379(22)01232-8
pmc: PMC9164243
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e12736Investigateurs
M D Adarraga
(MD)
J Aibar
(J)
M A Aibar
(MA)
C Amado
(C)
J I Arcelus
(JI)
A Asuero
(A)
R Barba
(R)
C Barbagelata
(C)
M Barrón
(M)
B Barrón-Andrés
(B)
A Blanco-Molina
(A)
E Botella
(E)
A M Camon
(AM)
I Casado
(I)
J Castro
(J)
M Castro
(M)
L Chasco
(L)
J Criado
(J)
C de Ancos
(C)
J Del Toro
(J)
P Demelo-Rodríguez
(P)
A M Díaz-Brasero
(AM)
J A Díaz-Peromingo
(JA)
M V Di Campli
(MV)
A Dubois-Silva
(A)
J C Escribano
(JC)
F Espósito
(F)
C Falgá
(C)
A I Farfán-Sedano
(AI)
C Fernández-Capitán
(C)
J L Fernández-Reyes
(JL)
M A Fidalgo
(MA)
K Flores
(K)
C Font
(C)
L Font
(L)
I Francisco
(I)
C Gabara
(C)
F Galeano-Valle
(F)
M A García
(MA)
F García-Bragado
(F)
M García de Herreros
(M)
R García de la Garza
(R)
C García-Díaz
(C)
R García-Hernáez
(R)
A García-Raso
(A)
A Gil-Díaz
(A)
M Giménez-Suau
(M)
E Grau
(E)
L Guirado
(L)
J Gutiérrez
(J)
L Hernández-Blasco
(L)
E Hernando
(E)
L Jara-Palomares
(L)
M J Jaras
(MJ)
D Jiménez
(D)
R Jiménez
(R)
C Jiménez-Alfaro
(C)
M D Joya
(MD)
S Lainez-Justo
(S)
A Latorre
(A)
J Lima
(J)
P Llamas
(P)
J L Lobo
(JL)
L López-Jiménez
(L)
P López-Miguel
(P)
J J López-Núñez
(JJ)
R López-Reyes
(R)
J B López-Sáez
(JB)
A Lorenzo
(A)
O Madridano
(O)
A Maestre
(A)
P J Marchena
(PJ)
F Martín-Martos
(F)
D Martínez-Urbistondo
(D)
C Mella
(C)
M I Mercado
(MI)
J Moisés
(J)
M V Morales
(MV)
A Muñoz-Blanco
(A)
N Muñoz-Rivas
(N)
M S Navas
(MS)
J A Nieto
(JA)
E Nofuentes-Pérez
(E)
M J Núñez-Fernández
(MJ)
B Obispo
(B)
M Olid
(M)
M C Olivares
(MC)
J L Orcastegui
(JL)
J Osorio
(J)
S Otalora
(S)
R Otero
(R)
D Paredes
(D)
P Parra
(P)
G Pellejero
(G)
J Portillo
(J)
F Rivera-Civico
(F)
D A Rodríguez-Chiaradía
(DA)
C Rodríguez-Matute
(C)
J Rogado
(J)
V Rosa
(V)
P Ruiz-Artacho
(P)
N Ruiz-Giménez
(N)
J Ruiz-Ruiz
(J)
P Ruiz-Sada
(P)
G Salgueiro
(G)
R Sánchez-Martínez
(R)
J F Sánchez-Muñoz-Torrero
(JF)
T Sancho
(T)
S Soler
(S)
B Suárez-Rodríguez
(B)
J M Suriñach
(JM)
R Tirado
(R)
M I Torres
(MI)
C Tolosa
(C)
F Uresandi
(F)
B Valero
(B)
R Valle
(R)
J F Varona
(JF)
G Vidal
(G)
P Villares
(P)
C Zamora
(C)
M Engelen
(M)
T Vanassche
(T)
P Verhamme
(P)
J Hirmerova
(J)
R Malý
(R)
N Ait Abdallah
(N)
L Bertoletti
(L)
A Bura-Riviere
(A)
J Catella
(J)
F Couturaud
(F)
B Crichi
(B)
P Debourdeau
(P)
O Espitia
(O)
N Falvo
(N)
H Helfer
(H)
K Lacut
(K)
R Le Mao
(R)
F Moustafa
(F)
G Poenou
(G)
I Quere
(I)
S Schellong
(S)
B Brenner
(B)
I Tzoran
(I)
R Nikandish
(R)
F Bilora
(F)
B Brandolin
(B)
M Ciammaichella
(M)
P Di Micco
(P)
E Imbalzano
(E)
R Maida
(R)
F Pace
(F)
R Pesavento
(R)
P Prandoni
(P)
R Quintavalla
(R)
A Rocci
(A)
C Siniscalchi
(C)
A Tufano
(A)
A Visonà
(A)
B Zalunardo
(B)
J Birzulis
(J)
A Skride
(A)
A Zaicenko
(A)
S Fonseca
(S)
F Martins
(F)
J Meireles
(J)
M Bosevski
(M)
H Bounameaux
(H)
L Mazzolai
(L)
C I Ochoa-Chaar
(CI)
I Weinberg
(I)
H M Bui
(HM)
Informations de copyright
© 2022 The Authors. Research and Practice in Thrombosis and Haemostasis published by Wiley Periodicals LLC on behalf of International Society on Thrombosis and Haemostasis (ISTH).
Références
Chest. 2016 Feb;149(2):315-352
pubmed: 26867832
J Thromb Haemost. 2006 Sep;4(9):1950-6
pubmed: 16961602
Lancet Oncol. 2016 Oct;17(10):e452-e466
pubmed: 27733271
Br J Haematol. 2015 Sep;170(5):640-8
pubmed: 26114207
Thromb Haemost. 2018 Jan;118(1):214-224
pubmed: 29304541
J Am Coll Cardiol. 2016 Jan 19;67(2):162-170
pubmed: 26791063
Clin Appl Thromb Hemost. 2006 Oct;12(4):389-96
pubmed: 17000884
Res Pract Thromb Haemost. 2022 Jun 03;6(4):e12736
pubmed: 35664535
Blood. 2014 Jun 19;123(25):3972-8
pubmed: 24782507
Arch Intern Med. 2002 Aug 12-26;162(15):1729-35
pubmed: 12153376
Thromb Res. 2010 Jun;125(6):490-3
pubmed: 20097409
Chest. 2016 Aug;150(2):374-83
pubmed: 27071810
J Clin Epidemiol. 2016 Nov;79:70-75
pubmed: 27237061
Thromb Haemost. 2008 Sep;100(3):435-9
pubmed: 18766259
Medicine (Baltimore). 2015 Aug;94(32):e1235
pubmed: 26266353
J Clin Oncol. 2015 Feb 20;33(6):654-6
pubmed: 25605844
BMC Cancer. 2013 Jun 13;13:284
pubmed: 23764005
PLoS One. 2015 Jun 15;10(6):e0128741
pubmed: 26076483
N Engl J Med. 2003 Jul 10;349(2):146-53
pubmed: 12853587
Int Angiol. 2019 Jun;38(3):173-184
pubmed: 31112023